Form 4: Guardant Health Chief Commercial Officer Reports Routine Stock Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent share disposition for tax withholding purposes.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported transactions on July 1, 2025.
• Acquired 1,929 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) granted on November 7, 2022. This award vests over a four-year period, with 25% vested on October 1, 2023, and the remaining 75% vesting in equal quarterly installments over the subsequent three years.
• Acquired an additional 1,667 shares of Common Stock through the vesting of RSUs granted on December 13, 2023. This award vests over a three-year period, with 33% vested on October 1, 2024, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.
• Disposed of 1,532 shares of Common Stock at a price of $50.71 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Chris Freeman beneficially owns 48,821 shares of Common Stock directly.
• Remaining derivative holdings include 9,642 Restricted Stock Units from the November 7, 2022 grant and 8,337 Restricted Stock Units from the December 13, 2023 grant.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation events for a key executive, including the vesting of Restricted Stock Units and the subsequent disposition of shares for tax withholding. This is an expected part of executive compensation and does not indicate any unusual positive or negative developments for the company.

Positives

• Vesting of 1,929 Restricted Stock Units, indicating continued equity compensation for the Chief Commercial Officer.
• Vesting of 1,667 Restricted Stock Units, further increasing the Chief Commercial Officer's equity stake in the company.
• The transactions reflect the execution of pre-scheduled equity compensation plans, aligning management incentives with shareholder interests.

Negatives

• Disposition of 1,532 shares for tax withholding purposes, which is a routine event but reduces the direct shareholding.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the scheduled vesting of remaining Restricted Stock Units. The remaining 75% of the November 7, 2022 RSU award vests in equal quarterly installments over the remaining three-year period after October 1, 2023. The remaining 67% of the December 13, 2023 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2024.

Industry Context

This Form 4 filing details routine insider transactions related to equity compensation, which is a common practice across all industries, including the healthcare and biotechnology sectors where Guardant Health operates. It reflects standard compensation mechanisms designed to align executive interests with long-term company performance.

Comparison to Industry Standards

• The vesting of Restricted Stock Units and subsequent share disposition for tax withholding are standard practices for executive compensation in publicly traded companies.
• The specific vesting schedules (e.g., 4-year and 3-year periods with quarterly installments) are typical for long-term incentive plans across various industries, including biotech and diagnostics, and are comparable to those offered by companies like Illumina, Exact Sciences, or Foundation Medicine (now part of Roche) for their executives.
• The share price of $50.71 for tax withholding is a factual data point specific to the transaction date.

Related Party Transactions

• The vesting of Restricted Stock Units is a transaction between the company and an executive, which is a common form of related party transaction in the context of executive compensation. However, it is a standard, pre-approved compensation mechanism rather than an unusual dealing.

Stakeholder Impact

• Shareholders: The vesting of RSUs increases the executive's alignment with shareholder interests. The disposition for tax withholding is a minor, routine event.
• Employees: Reflects standard equity compensation practices for executives, which can set a precedent for other employee incentive programs.

Next Steps

• Remaining 75% of the November 7, 2022 Restricted Stock Unit award will vest in equal quarterly installments over the remaining three-year period after October 1, 2023.
• Remaining 67% of the December 13, 2023 Restricted Stock Unit award will vest in equal quarterly installments over the remaining two-year period after October 1, 2024.

Key Dates

Recommendation

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Equity Compensation, Chris Freeman, Chief Commercial Officer, Tax Withholding, Beneficial Ownership